开发基于BACE2-IN-1/tranylcypromine的化合物,以诱导类固醇生成依赖的神经保护
Suddhasatwa Banerjee1, Ying-Ting Hsu2, Duc-Hieu Nguyen3
1School of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|January 21, 2025
概括
新的研究发现了一种新型化合物,可以抑制LSD1和BACE2,通过减少线粒体损伤和改善小鼠的认知功能,为创伤性脑损伤 (TBI) 提供神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 创伤性脑损伤 (TBI) 是导致死亡和残疾的主要原因,特别是在年轻人中.
- 目前的TBI治疗解决了二次损伤和症状,但仍然存在未满足的临床需求.
- 单细胞RNA测序显示,TBI后氨酸特异性去甲基酶1 (LSD1) 和分泌酶2 (BACE2) 的表达增加.
研究的目的:
- 通过针对LSD1和BACE2.2,开发用于TBI的新型神经保护剂.
- 合成和评估一种将LSD1抑制 (特兰基) 与BACE2抑制剂模板相结合的化合物.
- 评估该化合物在减轻TBI诱导的细胞损伤和改善神经功能方面的有效性.
主要方法:
- 药物化学活动,以创建一个BACE2抑制剂模板,包含修改的基胺.
- 在实验室中对化合物4对Neuro-2a细胞存活率,线粒体损伤和氧化应激的评估.
- 评估化合物4对TBI后的美瓦酸途径和氧化还原代谢的影响.
- 在TBI和化合物4治疗后的小鼠中进行体内行为测试 (筑巢,认知测试).
主要成果:
- 化合物4是一种BACE2-IN-1/tranylcypromine衍生物,在Neuro-2a细胞中表现出神经保护作用.
- 该化合物减轻了氧化应激诱导的线粒体损伤,并恢复了美瓦酸盐路径.
- 化合物4改善了氧化还原代谢,并在TBI小鼠中显著改善了行为结果.
- 抑制LSD1和BACE2减轻了线粒体压力,促进了神经代谢恢复.
结论:
- 针对LSD1和BACE2代表了对TBI的有希望的治疗策略.
- 化合物4显示出作为神经保护剂的潜力,用于解决TBI治疗的未满足需求.
- 合理设计的抑制剂为开发有效的TBI治疗提供了途径.
更多相关视频
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:21Drugs Affecting Neurotransmitter Release or Uptake
930
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
930
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:30Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K